Dolasetron mesylate, 100 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen
This is the 2013 version of HCPCS Q0180 - please refer to the 2016 HCPCS code set for the latest version.
Added on Wednesday, April 01, 1998
Status changed on Wednesday, April 01, 1998 to: No maintenance for this code
BETOS Classification: Chemotherapy
Medicare coverage status: Special coverage instructions apply